

Almost Like Being There: Updates in IgAN From Kindey Week

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Rovin BH, Barratt J, Heerspink HJL, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. *Lancet*. 2023;402(10417):2077-2090. doi:10.1016/S0140-6736(23)02302-4
<https://pubmed.ncbi.nlm.nih.gov/37931634/>

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. *Lancet*. 2023;401(10388):1584-1594. doi:10.1016/S0140-6736(23)00569-X
<https://pubmed.ncbi.nlm.nih.gov/37015244/>

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NeflgArd): 2-year results from a randomised phase 3 trial

Lafayette R, Kristensen J, Stone A, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NeflgArd): 2-year results from a randomised phase 3 trial [published correction appears in *Lancet*. 2023 Sep 9;402(10405):850]. *Lancet*. 2023;402(10405):859-870. doi:10.1016/S0140-6736(23)01554-4
<https://pubmed.ncbi.nlm.nih.gov/37591292/>

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

Rheault MN, Alpers CE, Barratt J, et al. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. *N Engl J Med*. Published online November 3, 2023. doi:10.1056/NEJMoa2308550
<https://pubmed.ncbi.nlm.nih.gov/37921461/>

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG₂ Monoclonal Antibody, in Healthy Volunteers

Mathur M, Barratt J, Suzuki Y, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG₂ Monoclonal Antibody, in Healthy Volunteers. *Kidney Int Rep*. 2022;7(5):993-1003. Published 2022 Feb 8. doi:10.1016/j.ekir.2022.01.1073
<https://pubmed.ncbi.nlm.nih.gov/35570983/>

Targeting the Endothelin A Receptor in IgA Nephropathy

Kohan DE, Barratt J, Heerspink HJL, Campbell KN, Camargo M, Ogbaa I, Haile-Meskale R, Rizk DV, King A. Targeting the Endothelin A Receptor in IgA Nephropathy. *Kidney Int Rep*.

2023 Aug 4;8(11):2198-2210. doi: 10.1016/j.ekir.2023.07.023. PMID: 38025243; PMCID: PMC10658204.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658204/>

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study

Rizk DV, Rovin BH, Zhang H, Kashihara N, Maes B, Trimarchi H, Perkovic V, Meier M, Kollins D, Papachristofi O, Charney A, Barratt J. Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study. *Kidney Int Rep.* 2023 Feb 9;8(5):968-979. doi: 10.1016/j.ekir.2023.01.041. PMID: 37180505; PMCID: PMC10166738

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166738/>

#3848 ORIGIN TRIAL: 24-WK PRIMARY ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PH2B STUDY OF ATACICEPT IN PATIENTS WITH IGAN

Richard Lafayette, Bart Maes, Celia Lin, Sean Barbour, Richard Phoon, Sung Gyun Kim, Vladimir Tesar, Jürgen Floege, Vivek Jha, Jonathan Barratt, #3848 ORIGIN TRIAL: 24-WK PRIMARY ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PH2B STUDY OF ATACICEPT IN PATIENTS WITH IGAN, *Nephrology Dialysis Transplantation*, Volume 38, Issue Supplement_1, June 2023, gfad063a_3848, https://doi.org/10.1093/ndt/gfad063a_3848

https://academic.oup.com/ndt/article/38/Supplement_1/gfad063a_3848/7196071